Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD

ClinicalTrials.gov ID: NCT03841773

Public ClinicalTrials.gov record NCT03841773. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 11:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD Taken Daily at Bedtime (Protocol No. TNX-CY-P302)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose study that will investigate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) - a sublingual formulation of cyclobenzaprine. Following successful screening and randomization, eligible patients will have a telephonic visit at week 2 and then return regularly to the study clinic for monthly visits for assessments of efficacy and safety.

Study identification

NCT ID
NCT03841773
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Enrollment
192 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 6, 2019
Primary completion
Apr 23, 2020
Completion
Apr 23, 2020
Last update posted
Feb 5, 2025

2019 – 2020

United States locations

U.S. sites
30
U.S. states
17
U.S. cities
30
Facility City State ZIP Site status
Ashild Peters Phoenix Arizona 85012
Ashild Peters Little Rock Arkansas 72211
Ashild Peters Rogers Arkansas 72758
Ashild Peters Beverly Hills California 90210
Ashild Peters Oceanside California 92056
Ashild Peters Orange California 92868
Ashild Peters Panorama City California 91402
Ashild Peters Riverside California 92506
Ashild Peters San Diego California 92123
Ashild Peters Temecula California 92591
Ashild Peters Colorado Springs Colorado 80910
Ashild Peters Norwich Connecticut 06360
Ashild Peters Washington D.C. District of Columbia 20011
Ashild Peters Jacksonville Florida 32256
Ashild Peters North Miami Florida 33161
Ashild Peters Orlando Florida 32801
Ashild Peters Tampa Florida 33614
Ashild Peters Alpharetta Georgia 30341
Ashild Peters Lincolnwood Illinois 60712
Ashild Peters Boston Massachusetts 02131
Ashild Peters New Bedford Massachusetts 02740
Ashild Peters Flowood Mississippi 39232
Ashild Peters St Louis Missouri 63141
Ashild Peters Las Vegas Nevada 89102
Ashild Peters Oklahoma City Oklahoma 73106
Ashild Peters Portland Oregon 97214
Ashild Peters Salem Oregon 97301
Ashild Peters Memphis Tennessee 38119
Ashild Peters Austin Texas 78737
Ashild Peters Dallas Texas 75231

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03841773, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 5, 2025 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03841773 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →